MADRIGAL PHARMACEUTICALS, INC. — Director's Dealing 2012

Mar 9, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SYNTA PHARMACEUTICALS CORP (SNTA)
CIK: 0001157601
Period of Report: 2012-03-06

Reporting Person: Bahcall Safi R (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-03-06	Employee Stock Option (Right to Buy)	$4.22	A	185000	Acquired	2022-03-06	Common Stock (185000)	Direct

Footnotes

F1: The option vests as to 25% of the shares on March 6, 2013 and as to an additional 6.25% of the shares on the last day of each successive three-month period thereafter.